$7.6M Partnership Advances Gene Therapy for Rare Muscle Disease

Patients with a devastating muscle disease just got a powerful reason for hope.

Cure Rare Disease, a nonprofit biotech organization, has partnered with the LGMD2L Foundation to develop the first gene therapy for Anoctamin 5-related disease. The patient advocacy group is backing the collaboration with $7.65 million to fund the complete journey from lab to clinic.

The disease, also called Limb Girdle Muscular Dystrophy type 2L, progressively weakens muscles around the shoulders, upper arms, and thighs. Healthy muscle tissue slowly degenerates and gets replaced with fat and scar tissue, making everyday activities like walking, lifting, and standing increasingly difficult.

The funding will support every critical step in the development process: therapeutic design, preclinical studies, manufacturing scale-up, and ultimately the first human clinical trial. This comprehensive approach addresses a major gap in treatment, since no private pharmaceutical companies are currently pursuing gene therapy for this condition.

"Gene therapy is the most promising therapeutic avenue for this devastating disease, yet no private-sector programs are currently advancing this approach," said Hal Tily, VP of Research for the LGMD2L Foundation. The foundation was established in 2018 to unite patients and families, and expanded in 2024 to actively fund research toward treatments.

The therapy will use a next-generation delivery system that may be safer than earlier versions. Cure Rare Disease is also developing similar treatments for related muscular dystrophies, creating potential benefits for multiple patient communities.

The Ripple Effect

This partnership showcases a growing trend in rare disease treatment: patient organizations taking control of their own futures. When traditional pharmaceutical pipelines overlook conditions affecting small populations, committed communities are stepping up with their own funding and strategic partnerships.

The collaboration offers a blueprint for other rare disease groups seeking to accelerate research. By combining patient advocacy resources with nonprofit drug development expertise, communities can move promising therapies forward without waiting for commercial interest.

Rich Horgan, CEO of Cure Rare Disease, emphasized the power of this model. "This partnership is a testament to the power of collaboration between drug development organizations and advocacy groups in the fight against rare diseases," he said.

For families watching their loved ones lose muscle function year by year, this investment represents more than scientific progress. It's a tangible path toward treatment where none existed before.